← Leaderboards
Jeffrey J Gold
University Of Minnesota
$496,801
Attributed
$1,987,205
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $703.4K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
FDA$1,987,205 · 1
By mechanism
R01$1,987,205 · 1
Top collaborators
- Richard H Haas3 shared
- Cynthia Sharpe3 shared
- Sonya Grace Wang3 shared
Grant awards (3)
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)$703,432
R01 · FY2025 · FD
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)$703,302
R01 · FY2024 · FD
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)$580,471
R01 · FY2022 · FD